Cargando…
Influenza vaccination in patients with pulmonary sarcoidosis: efficacy and safety
Please cite this paper as: Tavana et al. (2011) Influenza vaccination in patients with pulmonary sarcoidosis: efficacy and safety. Influenza and Other Respiratory Viruses DOI: 10.1111/j.1750‐2659.2011.00290.x. Background Sarcoidosis is an inflammatory, granulomatous disorder of unknown etiology. Th...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Blackwell Publishing Ltd
2011
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4942082/ https://www.ncbi.nlm.nih.gov/pubmed/21955954 http://dx.doi.org/10.1111/j.1750-2659.2011.00290.x |
_version_ | 1782442379055202304 |
---|---|
author | Tavana, Sasan Argani, Hassan Gholamin, Sharareh Razavi, Seyed‐Mostafa Keshtkar‐Jahromi, Marzieh Talebian, Amir S. Moghaddam, Keivan G. Sepehri, Zahra Azad, Talat M. Keshtkar‐Jahromi, Maryam |
author_facet | Tavana, Sasan Argani, Hassan Gholamin, Sharareh Razavi, Seyed‐Mostafa Keshtkar‐Jahromi, Marzieh Talebian, Amir S. Moghaddam, Keivan G. Sepehri, Zahra Azad, Talat M. Keshtkar‐Jahromi, Maryam |
author_sort | Tavana, Sasan |
collection | PubMed |
description | Please cite this paper as: Tavana et al. (2011) Influenza vaccination in patients with pulmonary sarcoidosis: efficacy and safety. Influenza and Other Respiratory Viruses DOI: 10.1111/j.1750‐2659.2011.00290.x. Background Sarcoidosis is an inflammatory, granulomatous disorder of unknown etiology. The role of cellular and humoral immune systems in this disease is unclear, whereas dysregulation of the immune system is suggested. Patients with sarcoidosis show diverse responses while exposed to various antigens. Although influenza vaccination is recommended in pulmonary sarcoidosis, its efficacy and safety has not been investigated. Objectives To evaluate safety and immunogenicity of influenza vaccine in patients with sarcoidosis. Patients/Methods Influenza vaccination was performed in 23 eligible patients with sarcoidosis (SP) and 26 healthy controls (HC). Antibody titers against H1N1, H3N2, and B influenza virus antigens were evaluated just before and 1 month after vaccination. Patients were followed for 6 months to assess vaccine safety. Results Serological response and magnitude of changes in antibody titers against influenza vaccine antigens were comparable between SPs and HCs. Women showed a better serological response against B antigen (P = 0·034) than men. Twenty‐four‐hour urine calcium was associated with antibody response against H1N1 [correlation coefficient (CC) = 0·477, P = 0·003] and H3N2 (CC = 0·352, P = 0·028) antigens. Serum angiotensin‐converting enzyme correlated negatively with antibody response against B antigen (CC = −0·331, P = 0·040). Higher residual volume was associated with fewer rises in antibody titer against H3N2 antigen (CC = −0·377, P = 0·035). No major adverse events or disease flare‐up was observed during follow‐up. Conclusions In this study, influenza vaccination did not cause any major adverse event in SPs, and their serological response was equal to HCs. Studies with larger sample size and a broader selection of subjects could help validate the results of this study. |
format | Online Article Text |
id | pubmed-4942082 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2011 |
publisher | Blackwell Publishing Ltd |
record_format | MEDLINE/PubMed |
spelling | pubmed-49420822016-07-18 Influenza vaccination in patients with pulmonary sarcoidosis: efficacy and safety Tavana, Sasan Argani, Hassan Gholamin, Sharareh Razavi, Seyed‐Mostafa Keshtkar‐Jahromi, Marzieh Talebian, Amir S. Moghaddam, Keivan G. Sepehri, Zahra Azad, Talat M. Keshtkar‐Jahromi, Maryam Influenza Other Respir Viruses Original Articles Please cite this paper as: Tavana et al. (2011) Influenza vaccination in patients with pulmonary sarcoidosis: efficacy and safety. Influenza and Other Respiratory Viruses DOI: 10.1111/j.1750‐2659.2011.00290.x. Background Sarcoidosis is an inflammatory, granulomatous disorder of unknown etiology. The role of cellular and humoral immune systems in this disease is unclear, whereas dysregulation of the immune system is suggested. Patients with sarcoidosis show diverse responses while exposed to various antigens. Although influenza vaccination is recommended in pulmonary sarcoidosis, its efficacy and safety has not been investigated. Objectives To evaluate safety and immunogenicity of influenza vaccine in patients with sarcoidosis. Patients/Methods Influenza vaccination was performed in 23 eligible patients with sarcoidosis (SP) and 26 healthy controls (HC). Antibody titers against H1N1, H3N2, and B influenza virus antigens were evaluated just before and 1 month after vaccination. Patients were followed for 6 months to assess vaccine safety. Results Serological response and magnitude of changes in antibody titers against influenza vaccine antigens were comparable between SPs and HCs. Women showed a better serological response against B antigen (P = 0·034) than men. Twenty‐four‐hour urine calcium was associated with antibody response against H1N1 [correlation coefficient (CC) = 0·477, P = 0·003] and H3N2 (CC = 0·352, P = 0·028) antigens. Serum angiotensin‐converting enzyme correlated negatively with antibody response against B antigen (CC = −0·331, P = 0·040). Higher residual volume was associated with fewer rises in antibody titer against H3N2 antigen (CC = −0·377, P = 0·035). No major adverse events or disease flare‐up was observed during follow‐up. Conclusions In this study, influenza vaccination did not cause any major adverse event in SPs, and their serological response was equal to HCs. Studies with larger sample size and a broader selection of subjects could help validate the results of this study. Blackwell Publishing Ltd 2011-09-28 2012-03 /pmc/articles/PMC4942082/ /pubmed/21955954 http://dx.doi.org/10.1111/j.1750-2659.2011.00290.x Text en © 2011 Blackwell Publishing Ltd |
spellingShingle | Original Articles Tavana, Sasan Argani, Hassan Gholamin, Sharareh Razavi, Seyed‐Mostafa Keshtkar‐Jahromi, Marzieh Talebian, Amir S. Moghaddam, Keivan G. Sepehri, Zahra Azad, Talat M. Keshtkar‐Jahromi, Maryam Influenza vaccination in patients with pulmonary sarcoidosis: efficacy and safety |
title | Influenza vaccination in patients with pulmonary sarcoidosis: efficacy and safety |
title_full | Influenza vaccination in patients with pulmonary sarcoidosis: efficacy and safety |
title_fullStr | Influenza vaccination in patients with pulmonary sarcoidosis: efficacy and safety |
title_full_unstemmed | Influenza vaccination in patients with pulmonary sarcoidosis: efficacy and safety |
title_short | Influenza vaccination in patients with pulmonary sarcoidosis: efficacy and safety |
title_sort | influenza vaccination in patients with pulmonary sarcoidosis: efficacy and safety |
topic | Original Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4942082/ https://www.ncbi.nlm.nih.gov/pubmed/21955954 http://dx.doi.org/10.1111/j.1750-2659.2011.00290.x |
work_keys_str_mv | AT tavanasasan influenzavaccinationinpatientswithpulmonarysarcoidosisefficacyandsafety AT arganihassan influenzavaccinationinpatientswithpulmonarysarcoidosisefficacyandsafety AT gholaminsharareh influenzavaccinationinpatientswithpulmonarysarcoidosisefficacyandsafety AT razaviseyedmostafa influenzavaccinationinpatientswithpulmonarysarcoidosisefficacyandsafety AT keshtkarjahromimarzieh influenzavaccinationinpatientswithpulmonarysarcoidosisefficacyandsafety AT talebianamirs influenzavaccinationinpatientswithpulmonarysarcoidosisefficacyandsafety AT moghaddamkeivang influenzavaccinationinpatientswithpulmonarysarcoidosisefficacyandsafety AT sepehrizahra influenzavaccinationinpatientswithpulmonarysarcoidosisefficacyandsafety AT azadtalatm influenzavaccinationinpatientswithpulmonarysarcoidosisefficacyandsafety AT keshtkarjahromimaryam influenzavaccinationinpatientswithpulmonarysarcoidosisefficacyandsafety |